KROS
Keros Therapeutics Inc

1,243
Mkt Cap
$493.55M
Volume
1.33M
52W High
$72.37
52W Low
$9.12
PE Ratio
10.50
KROS Fundamentals
Price
$16.20
Prev Close
$16.17
Open
$16.24
50D MA
$15.50
Beta
0.95
Avg. Volume
1.06M
EPS (Annual)
-$5.00
P/B
0.94
Rev/Employee
$21,005.92
Loading...
Loading...
News
all
press releases
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Hold" by Analysts
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been assigned an average rating of "Hold" from the fourteen ratings firms that are currently covering the company, MarketBeat Ratings...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Stock Price Expected to Rise, Wedbush Analyst Says
Wedbush raised their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a "neutral" rating in a research report on Thursday...
MarketBeat·1d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Beats Estimates By $0.93 EPS
Keros Therapeutics (NASDAQ:KROS - Get Free Report) released its earnings results on Wednesday. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates...
MarketBeat·1d ago
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +83.78% and +86.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·18d ago
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
KROS vs. EXAS: Which Stock Is the Better Value Option?
Zacks·3mo ago
News Placeholder
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Zacks·4mo ago
News Placeholder
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Zacks·4mo ago
News Placeholder
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
Zacks·4mo ago

Latest KROS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.